A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. (Q46413137)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15800893%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

title

A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15800893%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

main subject

phase I clinical trial

0 references

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15800893%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

9

Susan Bates

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15800893%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

10

Tito Fojo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15800893%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

3

Maureen Edgerly

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15800893%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

Sen H Zhuang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15800893%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Manish Agrawal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15800893%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Susan Bakke

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15800893%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Herb Kotz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15800893%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Paul Thambi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15800893%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Ann Rutt

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15800893%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

language of work or name

English

0 references

publication date

1 May 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15800893%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

number of pages

7

1 reference

inferred from page(s)

published in

Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15800893%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15800893%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15800893%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

1932-1938

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15800893%20AND%20SRC:MED&resulttype=core&format=json

Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).

10 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20977

7 January 2021

Synthesis of epothilones A and B in solid and solution phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20977

7 January 2021

Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20977

7 January 2021

Synthesis, structure proof, and biological activity of epothilone cyclopropanes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20977

7 January 2021

Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20977

7 January 2021

Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20977

7 January 2021

Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20977

7 January 2021

Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20977

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20977

7 January 2021

Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20977

7 January 2021

Theoretical and practical aspects of paclitaxel scheduling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20977

7 January 2021

A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20977

7 January 2021

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20977

7 January 2021